Table 8.
Association of AmtRNA with clinical manifestations in SLE.
| AmtRNA | ||||
|---|---|---|---|---|
| IgG | IgM | |||
| OR (CI) | p | OR (CI) | p | |
| Thrombotic events | 1.28 (0.24;6.77) | 0.77 | 0.93 (0.22;3.93) | 0.92 |
| [1.15 (0.17;7.87)] | [0.88] | [1.00 (0.18;5.61)] | [1.00] | |
| Presence of plaque | 0.14 (0.02–0.91) | 0.04 | 0.83 (0.25–2.76) | 0.76 |
| [0.16 (0.01–1.81)] | [0.14] | [0.82 (0.23–2.91)] | [0.76] | |
| SLEDAI-2K ≥ 4 | 2.30 (0.73–7.26) | 0.16 | 0.86 (0.34–2.17) | 0.75 |
| [3.04 (0.78–11.77)] | [0.11] | [0.68 (0.25–1.88)] | [0.46] | |
| SDI ≥ 0 | 0.95 (0.28–3.21) | 0.94 | 0.50 (0.16–1.58) | 0.24 |
| [0.85 (0.15–4.92)] | [0.85] | [0.46 (0.11–1.86)] | [0.28] | |
| Positivity to anti-dsDNA antibodies | 34.97 (6.26–195.55) | <0.0001 | 1.92 (0.67–5.50) | 0.23 |
| [70.60 (6.31–789.47)] | [0.0005] | [2.01 (0.50–8.11)] | [0.33] | |
| Lupus nephritis | 0.17 (0.02–1.71) | 0.13 | 0.43 (0.08–2.30) | 0.33 |
| [0.02 (0.00–0.68)] | [0.03] | [0.25 (0.04–1.48)] | [0.12] | |
Values presented as odds ratios (95% Wald Confidence Interval) and p-value from logistic regressions. In each instance, bivariate results are followed by multivariate analysis (between square brackets). Values in bold have a p-value ≤ 0.05.
AmtRNA, anti-mitochondrial RNA antibodies; CI: 95% Wald Confidence Interval; OR, odds ratio; SDI, lupus severity disease index; SLEDAI-2K, SLE disease activity index−2000. Data in bold are statistically significant (p < 0.05).